Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Verus Capital Partners LLC

Verus Capital Partners LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 326 shares of the biopharmaceutical company’s stock after buying an additional 67 shares during the period. Verus Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $314,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $932,571,000. International Assets Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after purchasing an additional 590,314 shares during the period. Global Assets Advisory LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $339,594,000. First Trust Advisors LP increased its holdings in Regeneron Pharmaceuticals by 115.2% in the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after buying an additional 195,902 shares during the period. Finally, abrdn plc raised its position in Regeneron Pharmaceuticals by 552.8% during the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock worth $193,136,000 after buying an additional 186,215 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on REGN. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Barclays lifted their price objective on Regeneron Pharmaceuticals from $1,050.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. UBS Group upped their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Finally, Argus lifted their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $1,038.77.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $10.25 during trading on Tuesday, hitting $1,092.36. The stock had a trading volume of 52,423 shares, compared to its average volume of 469,584. Regeneron Pharmaceuticals, Inc. has a twelve month low of $715.54 and a twelve month high of $1,106.16. The company’s 50-day moving average price is $1,016.19 and its two-hundred day moving average price is $967.07. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The stock has a market capitalization of $120.37 billion, a P/E ratio of 31.97, a PEG ratio of 2.27 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Insider Activity

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the sale, the executive vice president now directly owns 37,937 shares in the company, valued at $41,311,496.15. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The disclosure for this sale can be found here. Insiders sold 65,074 shares of company stock worth $64,546,123 over the last three months. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.